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Edited by Lukas HuberAbstract The Raf kinase inhibitory protein (RKIP) binds to
Raf-1 interfering with binding of the MEK substrate and poten-
tially also Raf-1 activation. In response to mitogen stimulation
RKIP dissociates from Raf-1 and later re-associates. Here, using
a combination of mutational approaches, biochemical studies,
peptide arrays and plasmon surface resonance (BIAcore), we ﬁne
map and characterize a minimal 24 amino acid long RKIP bind-
ing domain in the Raf-1 N-region, which consists of constitutive
elements at both ﬂanks and a center element that is regulated by
phosphorylation and enhances the re-binding of RKIP to Raf-1
in the later phase of mitogen stimulation.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The mitogen-activated protein (MAP) kinases are important
components of conserved signaling pathways controlling
embryogenesis, cell diﬀerentiation, proliferation, and death.
The MAPK signaling cascades are organized in a hierarchical
three-tiered module: MAP kinases are activated by MAP
kinase kinase (MAPKK), which is activated by a MAP kinase
kinase kinase (MAPKKK) [1]. ERKs (extracellular signal-reg-
ulated kinases) are the ﬁrst characterized subfamily of MAP
kinases activated by growth factors and other stimuli via a
cascade involving Ras, Raf-1 (MAPKKK), and MEK1/2
(MAPKK). Mammals have three Raf protein isoforms, A-
Raf, B-Raf, and Raf-1, which despite sharing many common
features of regulation can diﬀerentially modulate cellular re-
sponses [2,3]. Raf-1 regulation is very complex, and involves
amongst other processes the phosphorylation of the N-region
at Ser338 and Tyr341. PAK1 and 2 have been shown to phos-
phorylate Ser338 and SRC kinases have been shown to induce
phosphorylation of Tyr341 [2].*Corresponding authors. Fax: +44 141 942 6521 (W. Kolch),
+1 419 383 6228 (K.C. Yeung).
E-mail addresses: wkolch@beatson.gla.ac.uk (W. Kolch),
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doi:10.1016/j.febslet.2006.10.054One protein that binds to and negatively regulates Raf-1
signaling is Raf kinase inhibitor protein (RKIP) [4,5].
A member of the highly conserved phosphatidylethanol-
amine-binding protein family, RKIP, is widely expressed
in mammals [6,7]. RKIP inhibits phosphorylation and acti-
vation of MEK by Raf-1 by dissociating the physical inter-
action between Raf-1 and MEK, thus acting as a
competitive inhibitor of substrate binding [4,5]. The overex-
pression of RKIP leads to decreased activation of MEK by
Raf-1 and the reduction of transformation mediated by
Raf-1. In contrast, the downregulation of RKIP increases
MEK and ERK phosphorylation and AP-1 dependent tran-
scription [4]. In addition to Raf-1, B-Raf and two other
members of the MAPKKK family, TAK1 and NIK, are
also targets of RKIP [8,9]. Recently, the role of RKIP in
signal transduction was found to extend to feedback inhibi-
tion for G-protein-coupled receptors [10]. Although the
mechanism of suppression of the signaling pathways initi-
ated by some of these kinase targets by RKIP has been
partially delineated, little is known about the molecular
events regulating the inhibition. We have previously shown
that RKIP is released from Raf-1 upon mitogen stimula-
tion, and that this release coincides with the activation of
the MEK-ERK pathway [4,5]. Thus, it is important to under-
stand the mechanisms which regulate RKIP binding to and dis-
sociation from Raf-1. Recently, Trakul et al. [11] reported that
RKIP interferes with Raf-1 activation by inhibiting the phos-
phorylation of the Raf-1 N-region, Ser338 and Tyr340/341, by
PAK and SRC family kinases, respectively. As a consequence,
Raf-1 activation was inhibited, and in turn the phosphorylation
of these residues curbed RKIP binding to Raf-1 [11]. Thus, the
current state of knowledge suggests that RKIP inhibits both
Raf-1 activation [11] as well as the ability of Raf-1 to phosphor-
ylate its substrate MEK [4,5]. These mechanisms are not mutu-
ally exclusive and rather indicate that RKIPmay regulate Raf-1
at multiple levels. However, the mechanistic details and how
these inhibitory events are coordinated are unresolved. Here
we start to address these questions by mapping the minimal
region of Raf-1 required for RKIP binding, and then using
speciﬁc point mutants and quantitative surface plasmon reso-
nance (BIAcore) to analyze the role of Raf-1 phosphorylation
in the RKIP interaction with Raf-1. Our results indicate that
the N-region plays a coordinating role for both types of inhibi-
tion and that the aﬃnity of RKIP to Raf-1 is decisively modu-
lated by the phosphorylation of the N-region at Ser338/339 and
Tyr341.blished by Elsevier B.V. All rights reserved.
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2.1. Plasmids and cell culture
cDNA for GST-Raf-1 was cloned into pEBG as described [12]. The
Raf-1 mutants pEF-mRaf-1Y340F and Y341F were a gift from Rich-
ard Marais. The mammalian expression vector for myc-tagged Rab24
was a gift from William Maltese. The other plasmids have been
described before [4,5]. Cells were cultured in Dulbeccos’s modiﬁed
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum
and 1% penicillin/streptomycin.2.2. Transfection, GST pull-downs and immunoprecipitation
For in vivo RKIP – Raf-1 binding assays 293FT cells (Invitrogen)
were co-transfected with pEBG Raf-1 (GST-Raf-1) and pCMV HA-
RKIP constructs using the calcium phosphate precipitation method.
Forty-eight hours after transfection, cells were scraped from plates
and washed twice in phosphate-buﬀered saline (PBS). Pellets were
resuspended in PBS containing 1 mM DTT, mammalian protease
inhibitor cocktail (1:100 dilution; Sigma) and phosphatase inhibitors
and lysed by sonication. 200 lg total cell lysates were tumbled with
25 ll glutathione agarose beads (Sigma) for one hour, washed three
times with PBS, resolved by 10% SDS–PAGE, and transferred onto
PVDF membranes (Millipore) for Western blotting.
Binding studies with Raf-1 N-region point mutants were performed
using COS-1 cells. Varying amounts of plasmid expression vectors for
myc-tagged Rab24, B-Raf, Raf-1, Raf-1 Y340F, Raf-1 Y341, Raf-1
YY340/341FF, Raf-1 S338A, Raf-1 S339A, and Raf-1 SS338/339AA
were cotransfected with HA-RKIP cDNA such that the expressed pro-
teins were of equal levels. The transfection was done using FuGene6
(Roche) according to the manufacturer’s instructions. Twenty-four
hours post transfection, cells were made quiescent by serum starvation
for 24 h. Then, i.e. 48 h post transfection, cells were stimulated with
30 nM epidermal growth factor (EGF; Sigma) and 100 nM 12,13-tetra-
decanoyl phorbol (TPA; Sigma) for 10 min. Cells were lysed in TBST
buﬀer (20 mM Tris, pH 7.4, 150 mM NaCl, 2 mM EDTA, 1% Triton
X-100) containing protease and phosphatase inhibitors. For immuno-
precipitation, 200 lg of cell extracts was incubated with 2 lg 9E10
anti-myc monoclonal antibody for one hour at 4 C, then Protein G
agarose beads (Upstate USA, Inc.) were added for a further 1.5 h at
4 C. The beads were washed twice in TBST, once in TBS, resolved
on 12% SDS–PAGE and transferred onto PVDF membranes. The
blots were blocked in PBS plus 0.2% Tween-20 (PBST) with 5%
non-fat milk solution for one hour. HA-MEK immunoprecipitates
were prepared as above except that the 12CA5 antibody was used
for immunoprecipitation. Anti-phospho MEK antibody (Cell Signal-
ing Technology) was used to monitor activating MEK phosphoryl-
ation.
MCF-7 cells were transfected with 1 lg pcDNA3.1-FLAG-RKIP
and 2 lg pEGFP-Raf-1 per 10 cm dish using an Amaxa Nucleofector
according to the manufacturer’s protocol. Forty-eight hours post
transfection, cells were starved overnight in DMEM containing 0.1%
FBS. Cells were stimulated with 100 ng/ml EGF for 5, 10, 20, 40,
80 min and lysed in HKMEN buﬀer (10 mM HEPES, pH 7.2,
140 mM KCl, 5 mM MgCl2, 2 mM EGTA, 0.1% NP-40) containing
protease and phosphatase inhibitors. Afterwards, the lysates were
sonicated three times for 5 s each, and centrifuged at 13000 rpm for
10 min. Each supernatant was immunoprecipitated with 20 ll anti-
M2-FLAG agarose beads (Sigma) for 3 h at 4 C. Beads were washed
three times with HKMEN buﬀer, and separated on a 4–12% SDS–
PAGE gel (Invitrogen).2.3. Western blotting
Western blots of GST-Raf-1 and mutants and HA-RKIP were incu-
bated for one hour at room temperature with the indicated antibodies
(anti-GST antibody; anti-phospho-Raf-1 (Ser338), both from Upstate;
mouse monoclonal anti-HA antibody, 12CA5; mouse monoclonal
anti-myc antibody, 9E10, both from Roche Diagnostics). All primary
antibodies were diluted in primary antibody solution (PBST, 5% bo-
vine serum albumin, 0.002% sodium azide). Following three washes
in PBST, blots were incubated with the appropriate horseradish perox-
idase-conjugated secondary antibodies (Jackson ImmunoResearch
Laboratories, Inc.) in PBST 5% milk for one hour at room tempera-
ture. HA-tagged proteins were detected by incubating blots with
anti-HA antibody conjugated to horseradish peroxidase overnight at4 C. Proteins were visualized with enhanced chemiluminescence using
the BioRad ChemiDoc EQ system.
2.4. Raf-1 kinase assays
Raf-1 kinase assays were done as described previously [4]. Brieﬂy,
Raf-1 was expressed in COS-1 cells together with HA-RKIP. Raf-1
was immunoprecipitated using an antiserum made against the 12 C-
terminal amino acids or Raf-1 [13]. Cells were serum starved overnight,
treated with 30 ng/ml EGF for the timepoints indicated. Cells were
lysed in TBST substituted with phosphatase and protease inhibitors
[13]. Raf-1 immunoprecipitates were washed three times in TBST
and once in Raf kinase buﬀer (TBS plus 5 mMMgCl2). Then immuno-
precipitates were resuspended in Raf kinase buﬀer and incubated
for 30 min at room temperature with 10 lM ATP, 0.2 ll [c-32P]-ATP
(3000 Ci/mmol), and 50 ng kinase competent MEK plus 150 ng
kinase negative ERK (knERK) expressed in E. coli as described
[13]. The reaction was resolved on 10% SDS–PAGE and blotted.
The blots were autoradiographed and subsequently stained for Raf-1
and RKIP.
2.5. Phosphorylation of Raf-1 by v-SRC or PAK in vitro
Activated mutants of PAK, Myc-Pak (T423E), or Src, HA-v-Src,
were overexpressed in COS-1 cells and puriﬁed by immunoprecipita-
tion with 9E10 or 12CA5 antibodies, respectively. The immunoprecip-
itates were incubated with increasing amounts of RKIP (1, 3 and
9 lM) or 9 lM bovine serum albumin (BSA) as control at room tem-
perature for 10 min. Then 9 lM of the puriﬁed recombinant GST-Raf-
1 peptide (325–349) or GST-Raf-1 peptide (325–349SS338/339AA), 2 lM
ATP, and 10 lCi of [32P] ATP were added and incubated in a reaction
volume of 30 ll. After 30 min incubation at room temperature the
reaction was terminated with 10 ll of SDS sample buﬀer. Samples were
separated by SDS–PAGE, transferred to a PVDF membrane (Milli-
pore Corp.), and subjected to autoradiography. PAK and v-SRC pro-
teins were detected by Western blotting.
2.6. Peptide arrays
Peptide arrays were manufactured by the Cancer Research UK core
facility. Overlapping synthetic Raf-1 peptides (23-mers oﬀset by four
amino acids) immobilized on a nitrocellulose membrane were probed
with [35S]-methionine labeled RKIP protein that had been produced
using a coupled in vitro transcription/translation kit (TNT T7 quick
coupled transcription/translation kit, Promega) according to the man-
ufacturers instructions. Membranes were blocked with 5% BSA for 1
hour and incubated with the radioactive RKIP solution for 1 hour.
Afterwards, they were washed three times for 15 min with TBST and
autoradiographed using a phosphoimager. Signals were quantitated
using ImageJ 1.34s software.2.7. Surface plasmon resonance
Experiments were performed with a BIAcore T100 instrument using
Sensor Chip SA (BIAcore, Uppsala, Sweden) which permits the immo-
bilization of biotinylated peptides to a streptavidin surface. Biotinyla-
ted peptides of >95% purity were purchased from piCHEM, Graz,
Austria and Cancer Research UK, London, United Kingdom:
Raf-1 NR1: RPRGQRDSSYYWEIEASEV;
Raf-1 NR2: RPRGQRDpSpSYYWEIEASEV;
Raf-1 NR3: RPRGQRDSSpYpYWEIEASEV;
Raf-1 NR4: RPRGQRDpSpSpYpYWEIEASEV;
Raf-1 NR5: RPRGQRDpSpSYpYWEIEASEV.
Sensor chips were primed with running buﬀer (10 mM HEPES, pH
7.4, 0.15 M NaCl, 3.4 mM EDTA, and 0.05% surfactant P20; BIA-
core), followed by 40% glycerol, and conditioned with 1 M NaCl
and 50 mM NaOH. The peptides were immobilized to the surface in
running buﬀer to give approximately 850 RU (resonance units). Free
streptavidin on the chip was inactivated with biotin solution (Pierce,
United Kingdom). RKIP was expressed and puriﬁed from E. coli as
previously described [4], and prepared to a 2 mg/ml solution. Diﬀerent
concentrations of puriﬁed RKIP were applied to the sensor chip at a
ﬂow rate of 30 ll/min allowing 4 min for association and 5 min for dis-
sociation. Between applications the chip was regenerated with 1 M
NaCl followed by running buﬀer, which was used as a blank for the
subsequent measurement. All experiments were performed in dupli-
cates at 25 C. The results were plotted as RU versus time, and ana-
lyzed with the BIA-evaluation Software 4.1 (BIAcore, Uppsala,
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surfaces (no peptide or irrelevant peptide) and the response obtained
from an injection of buﬀer immediately prior to each analyte injection
was subtracted (double referencing). Binding of all the peptides ﬁtted a
1:1 Langmuir binding model, which describes a reversible interaction
of two molecules in a 1:1 complex.3. Results and discussion
We have previously shown that in response to mitogenic
stimulation RKIP quickly dissociated from Raf-1 but re-asso-
ciated later, and that the window of RKIP dissociation from
Raf-1 coincided with the peak of ERK activation [4]. These
results suggested that Raf-1 only can eﬃciently activate ERK
if RKIP is released. In Fig. 1a we have examined the kinase
activity of Raf-1 and RKIP binding. COS-1 cells were co-
transfected with Raf-1 and HA-RKIP, serum starved over-
night and stimulated with 100 ng/ml EGF for the timepoints
indicated. Raf-1 immunoprecipitates were examined for asso-
ciated RKIP and also tested for kinase activity using a linked
kinase assay, where Raf-1 is incubated with recombinant MEK
and kinase negative recombinant ERK (knERK). The readout
is phosphorylation of knERK. RKIP co-precipitated with Raf-
1 from serum-starved cells, and transiently dissociated upon
EGF treatment. At 10 min RKIP re-associated again and
stayed associated for the rest of the timecourse. Interestingly,
Raf-1 kinase activity was still high when RKIP re-associated
and stayed high for at least another 30 min. In addition,
Raf-1 kinase activity tested in vitro was similar in cells over-
expressing RKIP or not (Supplementary Fig. 1). These results
are not easily explainable by a simple model where the role of
RKIP is to inhibit Raf-1 activation by binding to and interfer-
ing with the phosphorylation of the N-region [11], which is re-
quired for Raf-1 activity. Further, this model makes it diﬃcult
to rationalize how RKIP mutants that cannot bind to Raf-1
still can suppress ERK signaling [5]. These observations sug-
gested that RKIP interfered with Raf-1 signaling at severalFig. 1. RKIP can bind to activated Raf-1 and compete for MEK binding. (a)
cells were stimulated as indicated using 30 ng/ml EGF. Raf-1 immunoprecip
and kinase negative ERK (knERK) as substrates. Associated HA-RKIP was
antibodies. (b) COS-1 cells were co-transfected with HA-MEK, RKIP and BX
post-transfection growing cells were lysed in TBST and HA-immunoprecipita
antibodies and associated BXB using Raf-1 antiserum.levels, including Raf-1 activation and substrate phosphor-
ylation.
It is diﬃcult to conclusively distinguish between these possi-
bilities. Since MEK is the only bona ﬁde Raf-1 substrate, both
inhibition of Raf-1 activation and interference with substrate
phosphorylation have to be assayed using MEK as substrate.
This poses a ‘‘Boolean dilemma’’ where the boundary between
‘‘AND’’ and ‘‘OR’’ options is blurred. Thus, we need to build
up evidence from correlative data from diﬀerent types and
sources of experiments. In order to assess inhibitory contribu-
tions we ﬁrst re-examined whether RKIP can interfere with the
ability of activated Raf-1 to phosphorylate MEK in vitro. Pre-
vious studies [4,5] had analyzed RKIP binding to Raf-1 and
shown that this will reduce the binding of MEK. However, this
still leaves the possibility that a high turnover could permit
MEK to become phosphorylated despite its binding to Raf-1
being reduced. Therefore, we immunoprecipitated MEK
and analyzed the eﬀects of RKIP on the phosphorylation of
its activating sites and Raf-1 association. To ensure eﬃcient
Raf-1 activity not dependent on growth factor stimulation,
which may confound the results, we used BXB, a Raf-1 mutant
rendered constitutively active by deletion of the N-terminal
regulatory domain [14]. BXB still can bind RKIP with similar
eﬃciency as Raf-1 [4]. BXB could be coimmunoprecipitated
with HA-MEK, which exhibited readily detectable phosphory-
lation of the activating sites (Fig. 1b). Coexpression of increas-
ing amounts of RKIP led to a loss of BXB binding to MEK
and also to a concomitant reduction of MEK phosphoryla-
tion. These data show that RKIP can competitively dissociate
the BXB–MEK complex and that this also prevents the phos-
phorylation of MEK. Consistent results were obtained with
full length Raf-1. When subjected to an in vitro kinase assay
in the presence of increasing amounts of puriﬁed recombinant
RKIP, a dose-dependent inhibition of Raf-1 kinase activity
was observed (Supplementary Fig. 2).
Second, we tested whether RKIP can interfere with the
activation of Raf-1 by phosphorylation of the N-region asRaf-1 and HA-RKIP were co-expressed in COS-1 cells. Serum starved
itates were subjected to coupled kinase assay using recombinant MEK
detected by immunoblotting the Raf-1 immunoprecipitates with RKIP
B (corresponding to the Raf-1 kinase domain) as indicated. Three days
tes were examined for MEK phosphorylation using a phospho speciﬁc
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periments done by Trakul et al. [11] where they showed that
transfection of an activated PAK and activated Src mutant in-
duced the phosphorylation of Raf-1 on Ser338/339 and Tyr341,
and that the co-expression of increasing amounts of RKIP
interfered with these phosphorylations. We obtained entirely
consistent results that conﬁrm these data (Supplementary
Fig. 3). However, as co-expression is a rather indirect assay
for phosphoryl- ation, we also tested whether RKIP could
interfere with the phosphorylation of Raf-1 at Ser338/339 and
Tyr341 using puriﬁed proteins in vitro (Fig. 2). As full length
Raf-1 is notoriously diﬃcult to produce and purify in a func-
tional form and in the quantities required for use as substrate
in in vitro kinase assays, we used a fragment (aa 325–349)
encompassing the N-region instead. This construct could be ex-
pressed and puriﬁed from E. coli, and was readily phosphory-
lated by either PAK or v-Src in vitro. Mutation of SS338/
9AA completely abolished phosphorylation by PAK, but did
not aﬀect phosphorylation by Src, assuring that the correct sites
are targeted. Surprisingly, the addition of increasing amounts
of puriﬁed RKIP protein to the in vitro kinase assays did not
have any eﬀect on the phosphorylation of either site by PAK
or Src. It has to be noted that the Raf-1 fragments used as sub-
strates have low aﬃnity to RKIP, and hence RKIP may not
protect eﬃciently. The same puriﬁed RKIP protein used, how-
ever, was able to suppress the activation of MEK-ERK by Raf-
1 in vitro (Supplementary Fig. 2). In summary, these results
suggested that the role of RKIP in Raf-1 regulation is multifac-
eted, and that as a prerequisite to elucidate it fully it is necessary
to understand the detailed regulation of RKIP binding to Raf-
1.
Therefore, we decided to ﬁne map the binding sites of RKIP
to Raf-1. For this purpose we co-expressed full length HA-
tagged RKIP with GST-fusion proteins of Raf-1 deletion
mutants in 293FT cells, and assayed RKIP recovery in GST
pull-downs (Fig. 3). Our original study had mapped the RKIPFig. 2. RKIP has no eﬀect on the phosphorylation of Raf-1 by v-SRC
or PAK in vitro. Puriﬁed recombinant GST-Raf-1(325–349) and GST-
Raf-1(325–349SS338/339AA) peptides were tested for phosphorylation by
Myc-Pak (T423E) or HA-v-Src in the presence of increasing amounts
of RKIP (1, 3 and 9 lM) or BSA (9 lM) as control. Phosphorylated
proteins were detected by autoradiography. PAK and v-SRC proteins
were detected by Western blotting.binding region in Raf-1 to kinase subdomains I and II, a region
of approximately 100 amino acids [5]. To map the RKIP bind-
ing region more precisely, we constructed additional deletions
starting from the amino end of the Raf-1 catalytic domain
(amino acids 325–648) (Fig. 3a). Diﬀerent GST-Raf-1 deletion
mutants were coexpressed with HA-tagged RKIP in 293FT
cells and examined for their ability to bind full-length wild type
RKIP (Fig. 3b). Consistent with our previously published
results [5], the Raf-1 catalytic domain, GST-Raf-1325–648, was
suﬃcient to bind RKIP. Removal of the N-terminal 13 amino
acids from this construct (GST-Raf-1338–648) did not aﬀect
RKIP binding, while removing four more amino acids which
contain the N-region phosphorylation sites (338–341) com-
pletely abolished its ability to bind to RKIP. To determine
whether RKIP also interacts with regions in CR1 and CR2,
additional GST fusion proteins containing the ﬁrst 324 amino
acids of Raf-1 were constructed. Detectable amounts of RKIP
were pulled down with GST-Raf-11–324, and the binding of
RKIP increased as the construct was extended towards the
C-terminus with the GST-Raf-11–339 construct showing similar
RKIP binding as the GST-Raf-1338–648 construct. Our results
therefore suggested that beside the region in CR3 located
between amino acids 325–349 additional regions in CR1 and
CR2 of Raf-1 might also bind to RKIP. To determine whether
the ﬁrst 24 amino acids (325–349) of the Raf-1 catalytic domain
are suﬃcient to bind toRKIP, we constructedGST-Raf-1325–349
and analyzed its binding to RKIP in the pull-down assay. Con-
curring with the aforementioned deletion mutation studies,
detectable amounts of RKIP were found to bind to the Raf-1
24-amino-acid peptide (Fig. 3b, right panel).
The minimal 24-amino-acid RKIP binding region encom-
passes the Ser338 and Tyr341 phosphorylation sites. We and oth-
ers have previously shown that the binding of RKIP to Raf-1 is
dynamically regulated by phosphorylation of both RKIP [15]
and Raf-1 [4,5]. Therefore, we investigated whether the Raf-1
N-region phosphorylation sites are important for RKIP bind-
ing using mutational analysis, where we conservatively subs-
tituted Ser338/339with Ala, and Tyr340/341 with Phe (Fig. 4a).
These mutants were co-expressed in COS-1 cells and analyzed
by co-immunoprecipitation. As shown previously, HA-RKIP
associated with myc-Raf-1 in quiescent cells and dissociated
upon EGF stimulation [4,5]. These interactions were speciﬁc,
as RKIP was not found in the anti-myc immunoprecipitates
when myc-Rab24 was co-transfected as control. While the
Raf-1 Y340F had no eﬀect, mutation of Y341F abolished
detectable RKIP binding in quiescent cells, and so did the dou-
ble mutation YY340/341FF. Similarly, mutation of S338A or
S339A reduced binding of Raf-1 to RKIP, and the double
mutation SS338/339AA abolished it (Fig. 4b). This result was
surprising as Trakul et al. [11] had suggested that the phosphor-
ylation of these site provides a dissociation signal, and
one would have expected that replacing them by Ala should sta-
bilize RKIP binding to Raf-1. Therefore, we tested the eﬀects of
replacing these sites with phosphomimetic residues (Fig. 4c).
Mutation of either Ser338/9 to Asp and Glu, respectively, and
Tyr340or Tyr341 to Asp also reduced binding of Raf-1 to RKIP
in quiescent cells. A plausible interpretation for why both con-
servative and phosphomimetic mutations in the N-region inter-
fered with RKIP binding is that the phosphate is physically
involved in the binding.
Therefore, we investigated the role of Raf-1 N-region phos-
phorylation for RKIP binding in more detail. We performed
Fig. 3. Deletion mapping of the minimal RKIP binding domain in Raf-1. (a) Schematic of the GST-Raf-1 deletion constructs used in GST pull-down
assays. The upper top panel is the schematic of the Raf-1 protein showing the location of the three conserved regions (CR) and the N-region
(negative-charge regulatory region). Summary of RKIP binding is shown on the right. (b) Western blots of the GST-pull-down assay. GST-Raf-1
deletion mutants were co-expressed with HA-RKIP. Total cell lysates and GST pulldowns were Western blotted with anti-GST and anti-HA
antibodies as indicated. * Indicates nonspeciﬁc proteins that cross-react with the anti-HA Ab. The results shown are representative of at least three
independent experiments.
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region in Raf-1 (aa 331–349), determining the equilibrium
binding aﬃnities as well as association and dissociation rates
by plasmon surface resonance (BIAcore). To assess the eﬀects
of phosphorylation, phospho-amino acids were incorporated
at the crucial positions in various combinations. The Raf-1
peptides were immobilized on the chip and assayed for binding
of recombinant puriﬁed RKIP protein (Table 1 and Supple-
mentary Fig. 4). The non-phosphorylated Raf-1 peptide bound
to RKIP with low aﬃnity (KD = 3.6 · 103) and fast associa-
tion and dissociation kinetics indicating that RKIP binding to
the non-phosphorylated N-region is unstable and turns over
fast. Phosphorylation of Ser338 and Ser339 slowed down the
association rate, but decreased the dissociation rate even more,
resulting in an approximately 6-fold net enhancement of the
equilibrium binding. The phosphorylation of Tyr340/1 de-
creased both the association and dissociation rates compared
to the non-phosphorylated peptide, resulting in an overall in-
crease of equilibrium binding similar to the peptide phosphor-
ylated at Ser338/9. The phosphorylation of all four residues
cooperated to further enhance the association rate and reduce
the dissociation rate leading to a 30 fold gain in equilibrium
binding. Interestingly, omitting the phosphate at Tyr340 further
increased the binding of the triple phosphorylated peptide.
These data support the notion that Tyr340 may not be a phys-iological phosphorylation site [16], and that the phosphomi-
metic replacement at this site behaved diﬀerently from the
phosphomimetic replacements at the other three sites. Taken
together these data suggest that the phosphorylation of the
N-region actually provides a docking signal for RKIP binding
rather than a dissociation signal.
Using the Biacore T-100 we also undertook a detailed ther-
modynamic analysis of the transitional state thermodynamics
of the binding of the triple phosphorylated peptide NR5
(pSer338-pSer339-Tyr-pTyr341) (Table 2). The results suggested
that the interaction between RKIP and NR5 is largely enthal-
pically driven, as the enthalpy change (DH) for the interaction
is 87.91, whereas the entropy change is unfavorable
(TDS = 62.45). However, the enthalpic favorability of the
interaction outweighs the entropic penalty of the interaction,
giving a negative Gibbs free energy value, DG = 25.46
(DG = DH  TDS), which drives the association. Interestingly,
these measurements indicated that heat is given out during the
transition state, and that for the complex to form a very spe-
ciﬁc orientation of the molecules may be needed, which is
highly ordered and not favored by the rather high negative
entropic value DS. Thus, these data suggested that steric con-
straints operate at the binding surface.
Therefore, we ﬁne mapped the RKIP binding site in the N-
region using peptide arrays (Fig. 5). 23-mer peptides oﬀset by
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Fig. 4. Ser338-339and Tyr341 in the N-region of Raf-1 kinase domain are important for RKIP binding. (a,b) Conservative substitutions in the N-region
drastically reduced the aﬃnity of Raf-1 for RKIP in quiescent cells. COS-1 cells were cotransfected with HA-RKIP and diﬀerent myc-Raf-1 mutant
constructs as indicated. Myc-tagged Rab24 was used as a co-immunoprecipitation control. Twenty-four hours post-transfection cells were serum
starved for 24 h and stimulated with EGF plus TPA for 10 min. Lysates were immunoprecipitated (IP) with the anti-myc tag monoclonal antibody
9E10 and associated HA-RKIP proteins were detected by Western blotting. (c) Phosphomimetic substitutions in the N-region also decrease the
aﬃnity of Raf-1 for RKIP. COS-1 cells were cotransfected with HA-RKIP and diﬀerent myRaf-1 constructs mutant as indicated. Cells were treated
and lysates were immunoprecipitated with 9E10 ant-myc antibody and examined as above. The results shown are representative of at least three
independent experiments.
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downstream sequences were immobilized on nitrocellulose
ﬁlters and probed with 35S-labeled RKIP protein produced
by coupled in vitro transcription/translation. The results
show that RKIP binds upstream and downstream of the
Ser338Ser339Tyr340Tyr341 sequence much like a clamp (Fig. 5).
The binding to the Ser338Ser339Tyr340Tyr341 sequence itself is
below the detection threshold of the peptide array ﬁlter assay,
however could be clearly detected in the Biacore experiments
showing that the peptide array possesses lower sensitivity
than the Biacore. These results suggest a binding epitope that
consists of ﬂanking sequences that exhibit constitutive binding
and a central core where binding is regulated by phosphory-lation and actually requires phosphate residues for eﬃcient
docking. Thus, taken together these data suggest that RKIP
binds to the N-region of Raf-1 with rather loose aﬃnity and
high turnover rates. Phosphorylation of Ser338/9 and Tyr341
raises the aﬃnity of the N-region for RKIP providing a
binding signal that may recruit RKIP after dissociation from
Raf-1.
This model would predict that phosphorylation of the N-
region still should persist when RKIP re-binds to Raf-1. There-
fore, we monitored RKIP binding and S338 phosphorylation
over a timecourse of TPA stimulation (Fig. 6a). Y341 phos-
phorylation could not be examined because the sensitivity of
this phosphospeciﬁc antibody was too low to detect proteins
Table 1
Kinetic analysis of RKIP binding to immobilized Raf-1 peptides by surface plasmon resonance
Peptide ka (1/M s) S:E:ðkaÞ kd (1/s) S:E:ðkdÞ RUmax S:E:ðRmaxÞ KD v
2
NR1 SSYY 46.1 3.98 0.168 2.56 · 103 3.2 · 103 258 3.62 · 103 0.281
NR2 pSpSYY 16.8 1.52 9.71 · 103 2.82 · 105 242 16.8 5.77 · 104 0.873
NR3 SSpYpY 23.5 2.87 0.0127 2.65 · 104 206 21.6 5.42 · 104 0.187
NR4 pSpSpYpY 321 4.33 3.25 · 103 2.00 · 105 302 3.48 1.01 · 105 0.397
NR5 pSpSYpY 2218 54 0.04518 3.3 · 104 105.6 2.0 2.04 · 105 0.366
Binding was performed at 25 C as described in Section 2. Shown are the aﬃnity (KD), association (ka), and dissociation constants (kd) with their
standard errors (S.E.) and v2 values; RU, resonance units.
Table 2
Thermodynamic analysis of Raf-1 peptide NR5 (pS338-pS339-Y-pY341) binding
NR5 ka (1/M s) S:E:ðkaÞ kd (1/s) S:E:ðkdÞ RUmax S:E:ðRmaxÞ KD v
2
37 C 219.5 21 0.03911 5.2 · 104 203.0 19 1.782 · 104 2.34
25 C 2218 54 0.04518 3.3 · 104 105.6 2.0 2.04 · 105 0.366
15 C 2007 11 0.02496 5.8 · 104 158.2 0.62 1.24 · 105 0.179
8 C 4142 17 0.01765 4.1 · 105 112.1 0.27 4.26 · 106 0.329
Parameter name Parameter value S.D.
DH0 (kJ/mol) 87.91 14.81
DS0 (J/K mol) 209.5 50.42
TDS0 (kJ/mol) 62.45 15.03
DG (kJ/mol) at 25 C 25.46 0.2193
Binding of RKIP to the immobilized NR5 peptide was performed at the indicated temperatures. Shown are the aﬃnity (KD), association (ka), and
dissociation constants (kd) with their standard errors (S.E.) and v
2 values; RU, resonance units. S.D., standard deviation;H, enthalpy; S, entropy; T,
absolute temperature (Kelvin); G, Gibb’s free energy.
Fig. 5. Peptide array mapping of RKIP binding to the N-region of Raf-1. A peptide array was probed with [35S]-methionine labeled RKIP. The
autoradiograph and quantitation trace are shown above the peptide sequences. Serines338/339 and tyrosines340/341 are shown in red, and the start and
end points of selected deletion constructs from Fig. 3 are indicated by blue arrows.
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when S338 phosphorylation was rising. RKIP rebinding en-
sued while S338 phosphorylation was still high. To directly test
whether S338 phosphorylated Raf-1 can bind to RKIP during
later phases of growth factor stimulation we examined S338phosphorylation of RKIP bound Raf-1 over a timecourse of
EGF stimulation (Fig. 6b). Raf-1 phosphorylated on S338
was readily detectable in RKIP immunoprecipitates during
later phases of stimulation showing that S338 phosphorylation
is compatible with RKIP binding.
Fig. 6. Kinetic analysis of Raf-1 S338 phosphorylation and RKIP
rebinding. (a) HA-RKIP and myc-Raf-1 and were co-expressed in
COS-1 cells. Cells were stimulated with TPA for diﬀerent time points
as indicated. Myc-Raf-1 immunoprecipitates were examined for S338
phosphorylation by blotting with a phospho-speciﬁc antibody, and
HA-RKIP binding using anti-HA antibody. (b) MCF-7 cells were
transfected with FLAG-RKIP and GFP-Raf-1. Serum starved cells
were stimulated with 100 ng/ml EGF for the timepoints indicated.
RKIP was immunoprecipitated and co-precipitated Raf-1 adjusted for
equal loading was blotted with anti-phospho-S338 and Raf-1 anti-
bodies.
6412 S. Park et al. / FEBS Letters 580 (2006) 6405–6412These data are consistent with the hypothesis that the initial
dissociation of RKIP is caused by mitogen induced phosphor-
ylation of RKIP [15], but that the rebinding of RKIP involves
phosphorylation of the Raf-1 N-region. This working hypo-
thesis is diﬃcult to prove directly. A mutational approach is
inconclusive, as it prevents the association–dissociation–
re-association cycle. For instance, mutation of RKIP phos-
phoryl- ation sites was reported to prevent the initial RKIP dis-
sociation from Raf-1 [15], so re-association cannot be
measured; and mutation of N-region phosphorylation sites pre-
vents RKIP binding and hence dissociation cannot be mea-
sured. Thus, experimental proof hinges on the correlation of
biochemical kinetic data such as we have presented here.
Our working model makes predictions that open new avenues
of research and also will be valuable to validate the model.
For instance, RKIP rebinding induced by N-region phosphor-
ylation presumably will protect these sites from dephosphoryl-
ation and hence should prolong Raf-1 activation. However,
this may be futile as the N-region also is one part of the bipar-
tite MEK-binding site identiﬁed in the Raf-1 kinase domain
[12]. Thus, binding of RKIP will also dissociate Raf-1 from
its substrate and thereby terminate signaling. An attractive
speculation is that RKIP may redirect Raf-1 from MEK to
an alternative substrate. The existence of alternative Raf-1
eﬀectors is suggested by multiple lines of evidence including
the phenotype of Raf-1 knockout mice [3] and the recent dis-
covery of new MEK independent apoptosis pathways con-
trolled by Raf-1 [17] although the latter does not depend on
Raf-1 kinase activity. Given the known complexity of Raf-1regulation [2,18] it may not surprise that regulation or Raf-1
by RKIP also turns out to be more complicated and involve
multiple layers.
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